• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket

    1/9/23 8:04:47 AM ET
    $ALBO
    $AMYT
    $APGN
    $BBBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALBO alert in real time by email

    Gainers

    • CinCor Pharma, Inc. (NASDAQ:CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.
    • Amryt Pharma plc (NASDAQ:AMYT) shares rose 112% to $14.86 in pre-market trading after Chiesi Farmaceutici S.p.A. announced plans to acquire the company.
    • Apexigen, Inc. (NASDAQ:APGN) rose 92.4% to $1.81 in pre-market trading after climbing more than 10% on Friday.
    • Albireo Pharma, Inc. (NASDAQ:ALBO) shares rose 87.3% to $42.73 in pre-market trading.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) rose 53.4% to $2.01 in pre-market trading. Bed Bath & Beyond shares dropped over 22% on Friday following a report indicating the company could file for bankruptcy in the coming weeks.
    • Party City Holdco Inc. (NYSE:PRTY) rose 28.4% to $0.23 in pre-market trading. Party City shares dropped 50% on Friday following a report suggesting the company has hired a restructuring advisor and plans a bankruptcy filing within weeks.
    • Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) rose 24.8% to $9.39 in pre-market trading after the company announced topline results from Phase 3 PHALCON-NERD-301 trial evaluating daily dosing of vonoprazan for symptomatic NERD.
    • CureVac N.V. (NASDAQ:CVAC) shares rose 24.8% to $10.31 in pre-market trading. CureVac shares jumped over 29% on Friday after the company announced data on joint COVID-19 and flu mRNA vaccine development programs..
    • Viracta Therapeutics, Inc. (NASDAQ:VIRX) rose 21.3% to $1.99 in pre-market trading after the company announced first clinical response in epstein-barr virus-positive (EBV+) solid tumor setting.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) rose 20.2% to $0.1816 in pre-market trading. Novo Integrated Sciences recently reported it entered an agreement to purchase 100% of shares of SWAG in exchange for $1.00.

     

    Losers

    • Moolec Science SA (NASDAQ:MLEC) fell 28.4% to $13.78 in pre-market trading after jumping 258% on Friday.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares fell 15.7% to $0.1223 in pre-market trading after gaining over 10% on Friday.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) fell 13.2% to $0.5612 in pre-market trading after jumping around 35% on Friday. Neptune recently announced receipt of NASDAQ notification.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) fell 12.1% to $4.00 in pre-market trading after jumping around 54% on Friday.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) fell 11.4% to $10.31 in pre-market trading after jumping 82% on Friday.
    • Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) fell 11.1% to $0.60 in pre-market trading after gaining around 4% on Friday.
    • VYNE Therapeutics Inc. (NASDAQ:VYNE) fell 11% to $0.2012 in pre-market trading after jumping around 28% on Friday. VYNE Therapeutics, during November, posted a Q3 loss of $0.16 per share.
    • Spruce Biosciences, Inc. (NASDAQ:SPRB) fell 10.3% to $2.17 in pre-market trading. Spruce Biosciences shares jumped 94% on Friday after the company and Kaken Pharmaceutical announced a strategic partnership and exclusive licensing agreement to develop and commercialize tildacerfont for CAH in Japan.
    • Happiness Development Group Limited (NASDAQ:HAPP) fell 9% to $4.51 in pre-market trading. Happiness Development Group, on December 27, said that it entered into certain securities purchase agreement with certain purchasers.
    • Mullen Automotive, Inc. (NASDAQ:MULN) shares fell 6.4% to $0.3533 in pre-market trading after declining around 10% on Friday. Mullen shares, last month, announced the I-GO Commercial Urban Delivery EV has arrived Europe with sample vehicles now en route to Newgate Motor Group in Ireland..
    Get the next $ALBO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBO
    $AMYT
    $APGN
    $BBBY

    CompanyDatePrice TargetRatingAnalyst
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/12/2025$28.00Strong Buy
    Raymond James
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/9/2025$16.00Equal Weight
    Barclays
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    CureVac N.V.
    $CVAC
    6/13/2025$5.00Buy → Hold
    Jefferies
    More analyst ratings

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Spruce Biosciences with a new price target

    Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $283.00

    12/23/25 8:47:57 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Phathom Pharmaceuticals with a new price target

    Raymond James initiated coverage of Phathom Pharmaceuticals with a rating of Strong Buy and set a new price target of $28.00

    12/12/25 8:54:28 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Phathom Pharmaceuticals with a new price target

    Barclays initiated coverage of Phathom Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00

    12/9/25 8:52:32 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.

    SCHEDULE 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    3/12/26 4:46:41 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Bed Bath & Beyond Inc.

    S-8 - BED BATH & BEYOND, INC. (0001130713) (Filer)

    3/11/26 5:25:17 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form S-3 filed by Corbus Pharmaceuticals Holdings Inc.

    S-3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/11/26 5:06:17 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tabacco Joseph J Jr bought $102,200 worth of shares (20,000 units at $5.11) (SEC Form 4)

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 8:32:43 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Large owner Parkman Healthcare Partners Llc bought $4,585 worth of shares (256 units at $17.91) and sold $4,920 worth of shares (257 units at $19.14) (SEC Form 4)

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    10/15/25 4:32:43 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Parkman Healthcare Partners Llc bought $4,585 worth of shares (256 units at $17.91) and sold $4,920 worth of shares (257 units at $19.14) (SEC Form 4)

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    10/8/25 8:55:08 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tabacco Joseph J Jr bought $102,200 worth of shares (20,000 units at $5.11) (SEC Form 4)

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 8:32:43 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by President & CFO Lee Adrianne

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 6:57:02 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Chief Accounting Officer Putnam Leah R

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 6:19:15 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 5:45:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Leadership Updates

    Live Leadership Updates

    View All

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $BBBY
    Financials

    Live finance-specific insights

    View All

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

    FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion o

    2/17/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bed Bath & Beyond, Inc. Scheduled to Release Fourth Quarter & Full Year 2025 Financial Results

    Bed Bath & Beyond, Inc. (NYSE:BBBY) (the "Company"), owner of Bed Bath & Beyond, Overstock, buybuy BABY, and a blockchain asset portfolio, today announced that it is scheduled to release fourth quarter & full year 2025 financial results after the market closes on Monday, February 23, 2026. The Company has also scheduled a conference call and webcast to be held on Monday, February 23, 2026, at 4:30pm ET to discuss these results and take questions from participants during the live event. Questions may also be submitted to [email protected] in advance. Webcast and Replay Information To access the live webcast, visit investors.beyond.com. To participate in the conference call via telephone, p

    2/2/26 8:30:00 AM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary